KALA
KALA BIO, Inc.
NasdaqCMUSDEQUITY
Healthcare
DELAYED
Strong sell
-69/100
Last price
0.36
▼ 0.00 (0.14%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
0.35
Prev close
0.36
Day high
0.39
Day low
0.34
Volume
418.65K
Market cap
$7.04M
P/E (TTM)
—
52W range
0.34 – 95.50
Day trading desk
Gap from prior close
-3.31%
Prior close 0.36
VWAP
0.36
-0.21% from price
Relative volume
0.32×
Quiet session
Session range
13.20%
0.34 – 0.39
Position in range
47%
Mid range
ATR (14D)
0.06
17.52% of price
Prior day high
0.39
PDH
Prior day low
0.35
PDL
Bid / ask spread
—
Quote not published
Session volume
471.83K
Avg 1.46M
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
-27.63%
-29.6%
1M
-28.21%
-29.4%
3M
-73.81%
-78.3%
6M
-95.48%
-113.7%
YTD
-98.69%
-112.9%
1Y
-99.53%
-115.9%
3Y
-99.92%
-182.2%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on KALA open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
+22.65M
Net buying
Buy transactions
75
27.78M shares
Sell transactions
65
5.13M shares
Net transactions
+140
Buys less sells
Sell : buy shares
0.2 : 1
Mixed
Insider-held shares
240.01K
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Oct 23, 25 | IWICKI MARK T. Director |
SELL | 154.89K | $125.46K | Direct |
| Oct 23, 25 | REUMUTH MARY Chief Financial Officer |
SELL | 33.20K | $27.54K | Direct |
| Oct 22, 25 | BRAZZELL ROMULUS KIM Officer |
SELL | 46.75K | $38.80K | Direct |
| Oct 22, 25 | BAZEMORE TODD M Director |
SELL | 47.77K | $39.65K | Direct |
| Oct 22, 25 | KHARABI DARIUS Officer |
SELL | 20.81K | $17.27K | Direct |
| Oct 1, 25 | BAKER BROS ADVISORS, L.P. Former |
SELL | 730.41K | $1.06M | Indirect |
| Jun 24, 25 | IWICKI MARK T. Director |
SELL | 13.23K | $53.04K | Direct |
| Jun 24, 25 | BAZEMORE TODD M Chief Executive Officer |
SELL | 4.06K | $16.27K | Direct |
| Jun 24, 25 | REUMUTH MARY Chief Financial Officer |
SELL | 3.63K | $14.56K | Direct |
| Jun 24, 25 | KHARABI DARIUS Officer |
SELL | 4.51K | $18.09K | Direct |
| Jun 13, 25 | PERRY GREGORY D Director |
— | 2.45K | — | Direct |
| Jun 13, 25 | KOVEN ANDREW IAN Director |
— | 3.05K | — | Direct |
| Jun 13, 25 | ROSEN HOWARD B Director |
— | 2.45K | — | Direct |
| Jun 13, 25 | IWICKI MARK T. Director |
— | 2.45K | — | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
BAKER BROS ADVISORS, L.P. |
Former | — | Sale |
BAZEMORE TODD M |
Director | 35.93K | Sale |
BRAZZELL ROMULUS KIM |
Officer | 35.95K | Sale |
IWICKI MARK T. |
Director | 103.54K | Sale |
KHARABI DARIUS |
Officer | 41.76K | Sale |
KOVEN ANDREW IAN |
Director | 16.97K | Stock Award(Grant) |
MYERS CHARLES DANIEL |
Director | 10.37K | Stock Award(Grant) |
PERRY GREGORY D |
Director | 13.34K | Stock Award(Grant) |
REUMUTH MARY |
Chief Financial Officer | 28.91K | Sale |
ROSEN HOWARD B |
Director | 16.50K | Stock Award(Grant) |
Fundamentals
Market cap$7.04M
Enterprise value$-189.32K
Revenue (TTM)—
Gross profit—
EBITDA$-24.07M
Net income$-10.08M
EPS (TTM)$-10.71
Free cash flow$-18.42M
Total cash$7.23M
Total debt$0
Book value / share$0.47
Shares outstanding19.34M
Float19.34M
Short % of float2.31%
Dividend yield0.00%
Beta (5Y)-2.41
Valuation & profitability ratios
Trailing P/E—
Forward P/E-0.05
PEG ratio—
Price / sales—
Price / book0.78
EV / revenue—
EV / EBITDA0.01
Gross margin0.00%
Operating margin0.00%
Profit margin0.00%
Return on equity-345.32%
Return on assets-65.43%
Debt / equity—
Current ratio6.88
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $3.89M | — | — |
| Operating revenue | $0 | $0 | $0 | $3.89M | — | — |
| Cost of revenue | — | — | $0 | $2.56M | $4.10M | — |
| Gross profit | — | — | $0 | $1.33M | $7.14M | — |
| Research & development | $18.78M | $22.09M | $18.59M | $17.65M | — | -15.0% |
| Selling, general & admin | $23.63M | $18.34M | $20.57M | $65.03M | — | +28.8% |
| Total operating expense | $39.03M | $34.23M | $34.33M | $82.69M | — | +14.0% |
| Operating income | -$39.03M | -$34.23M | -$34.33M | -$81.36M | — | -14.0% |
| Net interest income | -$2.14M | -$3.73M | -$3.10M | -$6.60M | — | +42.7% |
| Pre-tax income | -$26.98M | -$38.51M | -$42.20M | -$44.82M | — | +29.9% |
| Net income | -$26.98M | -$38.51M | -$42.20M | -$44.82M | — | +29.9% |
| Net income to common | -$26.98M | -$38.51M | -$42.20M | -$44.82M | — | +29.9% |
| Basic EPS | -165.50 | -507.50 | -867.50 | -1,474.00 | — | +67.4% |
| Diluted EPS | -165.50 | -507.50 | -867.50 | -1,474.00 | — | +67.4% |
| EBIT | -$23.70M | -$32.73M | -$36.38M | -$37.56M | — | +27.6% |
| EBITDA | -$23.39M | -$32.47M | -$36.08M | -$37.02M | — | +28.0% |
| Basic shares | 162.97K | 75.92K | 48.64K | 30.41K | — | +114.7% |
| Diluted shares | 162.97K | 75.92K | 48.64K | 30.41K | — | +114.7% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $7.56M | $51.18M | $50.90M | $70.50M | — | -85.2% |
| Cash & short-term investments | $7.56M | $51.18M | $50.90M | $70.50M | — | -85.2% |
| Accounts receivable | — | — | $117.00K | $195.00K | $15.35M | — |
| Inventory | — | — | — | $0 | $8.64M | — |
| Total current assets | $9.49M | $52.80M | $52.87M | $85.94M | — | -82.0% |
| Property, plant & equipment | $0 | $2.44M | $2.78M | $416.00K | — | -100.0% |
| Total assets | $9.49M | $55.48M | $55.95M | $86.82M | — | -82.9% |
| Total current liabilities | $2.49M | $16.96M | $8.35M | $25.68M | — | -85.3% |
| Current debt | — | $10.34M | — | $5.00M | — | — |
| Long-term debt | — | $20.10M | $34.19M | $37.94M | $78.93M | — |
| Total debt | $0 | $32.25M | $36.32M | $42.95M | — | -100.0% |
| Total liabilities | $2.49M | $43.15M | $48.45M | $67.85M | — | -94.2% |
| Retained earnings | -$694.90M | -$667.92M | -$629.41M | -$587.21M | — | -4.0% |
| Shareholder equity | $7.00M | $12.33M | $7.50M | $18.97M | — | -43.3% |
| Working capital | $7.00M | $35.84M | $44.52M | $60.26M | — | -80.5% |
| Net tangible assets | $7.00M | $12.33M | $7.50M | $18.97M | — | -43.3% |
| Shares issued | 556.99K | 121.82K | 55.19K | 34.14K | — | +357.2% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | -$26.98M | -$38.51M | -$42.20M | -$44.82M | +29.9% |
| Depreciation & amortisation | $317.00K | $259.00K | $303.00K | $537.00K | +22.4% |
| Stock-based compensation | $7.00M | $8.39M | $7.46M | $7.01M | -16.6% |
| Change in working capital | -$5.52M | -$1.78M | $8.89M | $491.00K | -210.3% |
| Operating cash flow | -$31.99M | -$29.38M | -$27.93M | -$78.91M | -8.9% |
| Capital expenditure | -$15.00K | -$208.00K | -$610.00K | -$313.00K | +92.8% |
| Investing cash flow | -$15.00K | -$208.00K | -$429.00K | $62.72M | +92.8% |
| Financing cash flow | -$11.62M | $29.88M | $8.51M | -$7.94M | -138.9% |
| Free cash flow | -$32.01M | -$29.59M | -$28.54M | -$79.22M | -8.2% |
| End cash position | $7.56M | $51.18M | $50.90M | $70.75M | -85.2% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | $0 | — | — |
| Operating revenue | $0 | $0 | $0 | $0 | $0 | — | — |
| Research & development | $59.00K | $61.00K | $366.00K | $6.13M | $6.23M | — | -3.3% |
| Selling, general & admin | $1.66M | $1.74M | $9.86M | $4.53M | $4.64M | — | -4.5% |
| Total operating expense | $1.72M | $1.80M | $10.22M | $10.18M | $10.33M | — | -4.5% |
| Operating income | -$1.72M | -$1.80M | -$10.22M | -$10.18M | -$10.33M | — | +4.5% |
| Net interest income | $140.00K | $74.00K | -$141.00K | -$693.00K | -$674.00K | — | +89.2% |
| Pre-tax income | -$1.58M | -$1.62M | $686.00K | -$7.56M | -$11.15M | — | +2.5% |
| Net income | -$1.58M | -$1.62M | $686.00K | -$7.56M | -$11.15M | — | +2.5% |
| Net income to common | -$1.58M | -$1.62M | $686.00K | -$7.56M | -$11.15M | — | +2.5% |
| Basic EPS | -21.32 | -0.14 | — | -53.50 | -85.64 | -70.49 | -15,128.6% |
| Diluted EPS | -21.32 | -0.14 | — | -53.50 | -85.64 | -70.49 | -15,128.6% |
| EBIT | -$1.58M | -$1.62M | $827.00K | -$6.60M | -$10.07M | — | +2.5% |
| EBITDA | -$1.58M | -$1.62M | $881.00K | -$6.47M | -$10.01M | — | +2.5% |
| Basic shares | 74.16K | 11.87M | — | 140.85K | 130.26K | 126.92K | -99.4% |
| Diluted shares | 74.16K | 11.87M | — | 140.85K | 130.26K | 126.92K | -99.4% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Cash & equivalents | $229.00K | $1.76M | $7.56M | $21.10M | $31.94M | — | -87.0% |
| Cash & short-term investments | $7.23M | $8.76M | $7.56M | $21.10M | $31.94M | — | -17.5% |
| Accounts receivable | — | — | — | $0 | $112.00K | $112.00K | — |
| Total current assets | $10.58M | $12.32M | $9.49M | $24.27M | $33.66M | — | -14.1% |
| Property, plant & equipment | — | — | $0 | $603.00K | $2.16M | $2.30M | — |
| Total assets | $10.58M | $12.32M | $9.49M | $25.02M | $36.05M | — | -14.1% |
| Total current liabilities | $1.54M | $1.56M | $2.49M | $32.57M | $16.02M | — | -1.2% |
| Current debt | — | — | — | $28.41M | $9.51M | $15.50M | — |
| Long-term debt | — | — | — | — | $18.79M | $15.12M | — |
| Total debt | — | — | $0 | $29.94M | $29.93M | $32.35M | — |
| Total liabilities | $1.54M | $1.56M | $2.49M | $33.69M | $39.26M | — | -1.2% |
| Retained earnings | -$698.10M | -$696.52M | -$694.90M | -$695.59M | -$688.02M | — | -0.2% |
| Shareholder equity | $9.04M | $10.76M | $7.00M | -$8.66M | -$3.21M | — | -16.0% |
| Working capital | $9.04M | $10.76M | $7.00M | -$8.30M | $17.65M | — | -16.0% |
| Net tangible assets | $9.04M | $10.76M | $7.00M | -$8.66M | -$3.21M | — | -16.0% |
| Shares issued | 19.34M | 18.59M | 556.99K | 148.66K | 133.58K | — | +4.0% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$1.58M | -$1.62M | $686.00K | -$7.56M | -$11.15M | +2.5% |
| Depreciation & amortisation | $0 | $0 | $54.00K | $128.00K | $67.00K | — |
| Stock-based compensation | -$136.00K | -$471.00K | $401.00K | $2.04M | $2.24M | +71.1% |
| Change in working capital | $182.00K | -$2.56M | -$1.39M | -$2.27M | $694.00K | +107.1% |
| Operating cash flow | -$1.53M | -$2.90M | -$4.56M | -$10.88M | -$7.73M | +47.0% |
| Investing cash flow | $0 | -$7.00M | $0 | $1.00K | -$16.00K | +100.0% |
| Financing cash flow | $0 | $4.10M | -$8.98M | $30.00K | -$2.53M | -100.0% |
| Free cash flow | -$1.53M | -$2.90M | -$4.56M | -$10.89M | -$7.73M | +47.0% |
| End cash position | $229.00K | $1.76M | $7.56M | $21.10M | $31.94M | -87.0% |
Options analytics
Put / call volume
—
—
Put / call open interest
—
Positioning, not flow
Max pain
—
—
ATM implied vol
—
Nearest strike to spot
Skew (10% OTM)
—
—
Call volume
0
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
—
—
Heaviest put OI
—
—
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Sep 2025 | -50.50 | -53.50 | -5.9% |
| Jun 2025 | -102.00 | -65.94 | +35.4% |
| Mar 2025 | -127.00 | -50.66 | +60.1% |
| Dec 2024 | -123.50 | -61.58 | +50.1% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | — | — | $0 | — |
| Next quarter | — | — | $0 | — |
| Current year | — | — | $0 | — |
| Next year | — | — | $0 | — |
Analyst targets & ownership
Mean target—
High target—
Low target—
Implied upside—
Analyst count—
ConsensusNONE
Strong buy / Buy— / —
Hold—
Sell / Strong sell— / —
Held by insiders1.24%
Held by institutions4.07%
Institutions holding24
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
0.45
-19.72% from price
SMA 20
0.50
-27.45% from price
SMA 50
0.65
-44.10% from price
SMA 100
1.34
-72.95% from price
SMA 200
9.55
-96.19% from price
EMA 12
0.45
-19.53% from price
EMA 26
0.54
-32.84% from price
EMA 50
0.89
-59.54% from price
RSI (14)
29.5
Oversold
MACD (12,26,9)
-0.09
Hist -0.00
ATR (14)
0.06
17.43% of price
Realised vol 30D
126.0%
Annualised
Bollinger upper
0.65
20, 2σ
Bollinger lower
0.36
20, 2σ
50 / 200 cross
Death
0.65 vs 9.55
Trend bias
Below 200
-96.19%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
2.22
More volatile than market
Correlation to SPY
0.21
Largely independent
Realised vol 30D
126.0%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-99.6%
Peak to trough
Max drawdown 5Y
-100.0%
Peak to trough
ATR 14
0.06
17.43% of price
Beta (reported)
-2.41
5Y monthly, from filing
Short interest
Shares short
445.42K
Prior 255.23K
Change vs prior
+74.5%
Shorts adding
% of float
2.31%
Normal
% of shares out
2.30%
Against total outstanding
Days to cover
0.6
Liquid
Float
19.34M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 29, 25 | HC Wainwright & Co. | DOWNGRADE | Buy | Neutral |
| Sep 17, 25 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Sep 11, 25 | Oppenheimer | MAINTAINED | Outperform | Outperform |
| Sep 8, 25 | Mizuho | INITIATED | — | Outperform |
| May 23, 25 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Apr 4, 25 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Feb 13, 25 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Nov 15, 24 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Aug 19, 24 | Oppenheimer | MAINTAINED | Outperform | Outperform |
| May 17, 24 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Apr 2, 24 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Apr 1, 24 | Oppenheimer | MAINTAINED | Outperform | Outperform |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio0.00%
Ex-dividend date—
Next pay date—
Last split1:50
Split dateMay 11, 2026
SEC filings
Proxy Statements
DEF 14A · 2026-09-24
Proxy Statements
PRE 14A · 2026-09-11
Corporate Changes & Voting Matters
8-K · 2026-09-10
Corporate Changes & Voting Matters
8-K · 2026-09-09
Corporate Changes & Voting Matters
8-K · 2026-08-28
Periodic Financial Reports
10-Q · 2026-08-19
Periodic Financial Reports
NT 10-Q · 2026-08-14
Corporate Changes & Voting Matters
8-K · 2026-07-23
Headlines
KALA Bio Signs Non-Binding LOI to Acquire Nationwide Telehealth Platform with Approximately $48 Million in Sales Since Inception
TMX Newsfile · 8d ago
Kala Bio and Virotek Sign Letter of Intent with U.S. DNA Testing Platform to Resell Virotek's Suite of Genetic Testing Products
GlobeNewswire · 13d ago
KALA BIO Adds Healthcare Operator Yenvy Truong to Advisory Team
GlobeNewswire · 20d ago
Kala Bio Signs Exclusive U.S. Distribution Agreement for Virotek Ophthalmology Genetic Tests
InvestorsHub · 34d ago
Kala Bio and Virotek Finalize Definitive Agreement Establishing Exclusive U.S. Distribution Partnership for Ophthalmology Genetic Testing Program
GlobeNewswire · 34d ago
Kala Bio Targets Near-Term Revenue With Virotek Ophthalmology Genetic Testing Partnership
InvestorsHub · 36d ago
Kala Bio and Virotek Announce Letter of Intent to Establish an Exclusive U.S. Distribution Partnership for Ophthalmology Genetic Testing Program
GlobeNewswire · 36d ago
KALA BIO: Q2 Earnings Snapshot
Associated Press · 48d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.